Score & Rating History
Every shift in sentiment, performance and analyst outlook – transparently logged.
Price moves, patterns & momentum
From daily swings to long-term trends – track it all right here.
What this company is all about
Get the full picture: what they build, where they operate, and how they make money.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees (FY): 382
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Everything that moves Harrow Health, Inc.
From earnings beats to CEO slip-ups – here’s where you catch every move that could impact the stock.
Inside Harrow Health, Inc. and what the numbers reveal
Explore core financial metrics and technical signals for a clear view of valuation and performance.
